About: Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis
Creator	Chen, Jie Liang, Yi Zhang, Peng Fan, Jun-Bao Liao, Jun-Ming Zhou, Zheng
Source	PMC
abstract	Parkinson’s disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D(2) dopamine receptor desensitization, which is essential to Parkinson’s disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson’s disease has recently been shown. We studied the interaction between D(2) dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D(2) dopamine receptor interaction among them. These compounds are promising therapies for Parkinson’s disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.
has issue date	2011-11-01(xsd:dateTime)
bibo:doi	10.1007/s13238-011-1096-0
bibo:pmid	22180089
has license	bronze-oa
sha1sum (hex)	c6b4af8cda1203b0405d40987074629e689eb65e
schema:url	https://doi.org/10.1007/s13238-011-1096-0
resource representing a document's title	Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis
has PubMed Central identifier	PMC4875183
has PubMed identifier	22180089
schema:publication	Protein & Cell
resource representing a document's body	covid:c6b4af8cda1203b0405d40987074629e689eb65e#body_text
is schema:about of	named entity 'PARKINSON DISEASE' named entity 'THESE' named entity 'TREATMENT' named entity 'PARKINSON' named entity 'RECEPTOR DESENSITIZATION' named entity 'ARRESTIN' named entity 'GREAT' named entity 'RESULTS' named entity 'LARGE' named entity 'SCALE' named entity 'NEURODEGENERATIVE DISEASE' named entity 'EVALUATION' named entity 'DISEASE' named entity 'PROTEIN ' named entity 'interaction' named entity 'compounds' named entity 'capillary zone electrophoresis' named entity 'DETECTED' named entity 'BASED' named entity 'COMMON' named entity 'DOPAMINE RECEPTOR' named entity 'DRUG SCREENING' named entity 'USED' named entity 'CAPILLARY ZONE ELECTROPHORESIS' named entity 'IMPORTANT' named entity 'ESSENTIAL' named entity 'PHARMACOLOGICAL' named entity 'DRUG SCREENING' named entity 'REPORTED' named entity 'CHEMICAL COMPOUNDS' named entity 'USING' named entity 'APPLICATION' named entity 'SECOND' named entity 'PATIENTS' named entity 'BETA-ARRESTIN 2' named entity 'CAPILLARY ZONE ELECTROPHORESIS' named entity 'INTERACTION' named entity 'INTERACTION' named entity 'INVOLVED' named entity 'KEYWORDS' named entity 'REGULATION' named entity 'BETA-ARRESTIN-2' named entity 'MORE THAN' named entity 'VALUE' named entity '27S' named entity 'COMMUNICATION' named entity 'G PROTEIN-COUPLED RECEPTOR KINASE' named entity 'SCREENING' named entity 'METHOD' named entity 'STUDY' named entity 'INACTIVATION' named entity 'DOPAMINE RECEPTOR' named entity 'THERAPIES' named entity 'REVEALED' named entity 'RECENTLY' named entity 'WORLD' named entity 'POTENTIAL' covid:arg/c6b4af8cda1203b0405d40987074629e689eb65e named entity 'compounds' named entity 'disease' named entity 'arrestin-2' named entity 'treatment of patients' named entity 'kinase' named entity 'dopamine receptor' named entity 'pharmacological' named entity 'Parkinson's disease' named entity 'dopamine receptor' named entity 'dopamine receptor' named entity 'coupled receptor' named entity 'Parkinson's disease' named entity 'beta-arrestin-2' named entity 'protein' named entity 'μmol/L' named entity 'FITC' named entity 'deionized water' named entity 'photoreceptor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software